REG-4basebio Plc: Rapidly Produced Customisable Synthetic DNA

4BasebioAnnouncement

23/03/2022 07:15

23 March 2022

4basebio PLC

("4basebio", the "Company" or the “Group”)

Rapidly produced customisable synthetic DNA

4basebio PLC (AIM: 4BB), the life sciences group focused on exploiting
intellectual property in the field of cell and gene therapies and DNA and mRNA
vaccines, is pleased to announce the expansion of its synthetic DNA product
offering.

Following 4basebio’s announcement in June 2021 regarding the development of
its hpDNA™ and osDNA™ synthetic DNA constructs, 4basebio has now added
opDNA™ and oeDNA™ to its product offering.  This reflects the uniquely
customisable characteristics of 4basebio’s synthetic DNA technology. The DNA
product offering now comprises:
* hpDNA™ is a double stranded linear DNA, covalently closed with single
strand hairpins at the 5’ and 3’ ends and ideally suited for viral and
non-viral vector applications.
* osDNA™ incorporates nucleotide modifications within the DNA backbone
providing resistance to exonuclease degradation, as well as tuning of the
immunostimulatory properties of the construct, making osDNA™ ideally suited
for DNA vaccine applications.
* opDNA™ is a partially opened, linear, double stranded DNA product. Each
opDNA™ molecule features a hairpin on either the 3’ or 5’ end, with an
opposite open end. The open end of the construct can include an overhang or
blunt end. This product is ideally suited as a template for IVT production of
mRNA.
* oeDNA™ is a linear open-ended, double stranded DNA product where both 3’
and 5’ ends are open. Constructs can be generated with blunt ends, overhangs
or any combination thereof. Like all 4basebio’s DNA products, oeDNA™ is
resistant to degradation by exonuclease and hence suitable for in vivo
applications. This format is ideal for genome editing by homology directed
repair (HDR).
Dr Heikki Lanckriet, CEO and CSO for 4basebio, commented: “The development
of our DNA product range over the past twelve months underscores the
flexibility of our technology and our ability to customise DNA for particular
uses. We are able to modify our DNA constructs for an individual customer’s
specific application.”

“Moreover, due to our synthetic process, we can move from receipt of a
customer’s sequence to a first GMP-compliant multi-gram batch within three
months, significantly quicker than plasmid alternatives.”

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

For further enquiries, please contact:

 4basebio PLC                                                  +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                             
                                                                                   
 Cairn Financial Advisers LLP (Nominated Adviser)              +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                                        
                                                                                   
 finnCap Ltd (Broker)                                                              
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe/Nigel Birks   +44 (0)20 7220 0500 

Notes to Editors

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery
of payloads. The immediate objectives of 4bb are to validate and scale its DNA
synthesis and advance its collaborations to facilitate the functional
validation of its DNA based products and cell and gene delivery solutions.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
the 4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved